Lastly, antigenic loss to evade CAR T cell therapies is not unique to B-cell malignancies with downregulation of BCMA being reported in early phase trials with BCMA directed CAR T cell therapy for multiple myeloma [30]. Here, TNFRSF17 is linked to plasma cell myeloma.